Douglas CPA - MiMedx Chief Officer
| MDXG Stock | USD 7.89 0.21 2.59% |
Executive
Douglas CPA is Chief Officer of MiMedx Group
| Age | 59 |
| Address | 1775 West Oak Commons Court, NE, Marietta, GA, United States, 30062 |
| Phone | 770 651 9100 |
| Web | https://www.mimedx.com |
MiMedx Management Efficiency
The company has return on total asset (ROA) of 0.1474 % which means that it generated a profit of $0.1474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2501 %, meaning that it created $0.2501 on every $100 dollars invested by stockholders. MiMedx's management efficiency ratios could be used to measure how well MiMedx manages its routine affairs as well as how well it operates its assets and liabilities. At this time, MiMedx's Return On Assets are most likely to increase slightly in the upcoming years. At this time, MiMedx's Return On Tangible Assets are most likely to increase slightly in the upcoming years. The MiMedx's current Return On Assets is estimated to increase to 0.17, while Non Currrent Assets Other are projected to decrease to roughly 666.9 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Patrick MD | Centessa Pharmaceuticals PLC | N/A | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| Jose CPA | Mineralys Therapeutics, Common | 35 | |
| Esq JD | Erasca Inc | 52 | |
| Xichen Lin | Structure Therapeutics American | 51 | |
| Nick MD | Century Therapeutics | N/A | |
| Caroline MD | Ikena Oncology | 53 | |
| Roy Pollock | C4 Therapeutics | N/A | |
| Jeff Cole | Cadrenal Therapeutics, Common | N/A | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Robert Shoemaker | Erasca Inc | 44 | |
| MD FACC | Cadrenal Therapeutics, Common | 70 | |
| Stephen MBA | Inozyme Pharma | 66 | |
| Ingmar MD | Zentalis Pharmaceuticals Llc | 50 | |
| Carter King | Protagonist Therapeutics | 54 | |
| Mohammad Masjedizadeh | Protagonist Therapeutics | N/A | |
| Mary Fenton | Cullinan Oncology LLC | 60 | |
| Courtney Solberg | C4 Therapeutics | N/A | |
| Hui Lei | Structure Therapeutics American | N/A | |
| Edmund Dunn | Monte Rosa Therapeutics | 59 | |
| MS CPA | Erasca Inc | 58 | |
Management Performance
| Return On Equity | 0.25 | ||||
| Return On Asset | 0.15 |
MiMedx Group Leadership Team
Elected by the shareholders, the MiMedx's board of directors comprises two types of representatives: MiMedx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MiMedx. The board's role is to monitor MiMedx's management team and ensure that shareholders' interests are well served. MiMedx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MiMedx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Notarianni, Head Relations | ||
| Todd Newton, Interim Director | ||
| William Phelan, VP Officer | ||
| Robert MD, President Innovation | ||
| Kim Moller, Chief Officer | ||
| Joseph Capper, CEO Director | ||
| William IV, General Officer | ||
| Douglas CPA, Chief Officer | ||
| Mark Graves, Chief Compliance Officer | ||
| Scott Turner, Senior Procurement | ||
| Peter CPA, Chief Officer | ||
| David Mason, Chief Officer | ||
| Rohit Kashyap, Pres Surgical | ||
| Kate Surdez, Chief Officer | ||
| Hilary Dixon, Vice Communications |
MiMedx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MiMedx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.25 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 1.11 B | ||||
| Shares Outstanding | 147.37 M | ||||
| Shares Owned By Insiders | 2.78 % | ||||
| Shares Owned By Institutions | 69.91 % | ||||
| Number Of Shares Shorted | 3.72 M | ||||
| Price To Earning | 23.73 X |
Currently Active Assets on Macroaxis
When determining whether MiMedx Group is a strong investment it is important to analyze MiMedx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact MiMedx's future performance. For an informed investment choice regarding MiMedx Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MiMedx Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MiMedx. If investors know MiMedx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MiMedx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.86) | Earnings Share 0.28 | Revenue Per Share | Quarterly Revenue Growth 0.07 | Return On Assets |
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MiMedx's value and its price as these two are different measures arrived at by different means. Investors typically determine if MiMedx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MiMedx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.